A method of reducing the 'in vivo' cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (HDL) and low density lipoproteins (LDL)
A high-density lipoprotein, cholesteryl ester transfer technology, applied in the field of treatment or prevention of animals, can solve the problem of insufficient prevention of atherosclerosis
Inactive Publication Date: 2004-12-29
FORBES MEDI TECH
View PDF10 Cites 1 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0002] Although advances in science and technology in recent years have contributed to the improvement of the quality of human life and the extension of human life expectancy, the prevention of atherosclerosis, the underlying cause of cardiovascular disease ("CVD"), has not been adequately addressed
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0093] Objective: To determine whether a compound of the present invention, the water-soluble phytostanol ascorbate (phytostanol ( phytostanol)-phosphoryl-ascorbic acid), also known as FM-VP4.
[0094] Separation of lipoproteins:
[0095] Plasma was separated into HDL and LDL by density gradient ultracentrifugation, and the plasma density was adjusted with sodium bromide.
[0096] Quantification of plasma lipids and proteins:
[0097] from Sigma TM The Enzyme Assay Kit was used to determine total lipoprotein triglyceride, cholesterol and protein concentrations.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (HDL) and low density lipoproteins (LDL) comprises administering a therapeutically effective amount of one or more compounds: wherein R is a sterol or stanol moiety R2 is derived from ascorbic acid and R3 is hydrogen or any metal, alkali earth metal, or alkali metal; and all salts thereof, whereby plasma HDL and LDL are controlled as a result of such administration.
Description
field of invention [0001] The present invention relates to methods for treating or preventing cardiovascular diseases and underlying conditions thereof, including atherosclerosis, dyslipidemia diseases or disorders, in animals, especially humans. Background of the invention [0002] Although advances in science and technology in recent years have contributed to the improvement of the quality of human life and the extension of human life expectancy, the prevention of atherosclerosis, the underlying cause of cardiovascular disease ("CVD"), has not been adequately addressed . Atherosclerosis is a degenerative process resulting from the interplay of genetic (gene) factors and environmental factors such as diet and lifestyle. Research so far has shown that cholesterol may be present in the atherosclerosis by forming atherosclerotic plaques in blood vessels that eventually block blood supply to the heart muscle or blood supply to the brain or extremities, depending on where the p...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K45/00A61K31/575A61K45/06A61P3/06A61P9/10A61P43/00C07J9/00
CPCA61K45/06A61K31/575A61P3/06A61P9/10A61P43/00A61K2300/00
Inventor 海顿·P·普里查德基肖尔·M·瓦桑
Owner FORBES MEDI TECH
